Holen Sie sich die Stockscreener-App
52.72
2.65%
1.36
Handel nachbörslich:
52.70
-0.02
-0.04%
Schlusskurs vom Vortag:
$51.36
Offen:
$51.44
24-Stunden-Volumen:
865.94K
Relative Volume:
1.36
Marktkapitalisierung:
$2.23B
Einnahmen:
$17.39M
Nettoeinkommen (Verlust:
$-135.89M
KGV:
-11.36
EPS:
-4.64
Netto-Cashflow:
$-123.00M
1W Leistung:
+26.61%
1M Leistung:
+34.56%
6M Leistung:
+0.94%
1J Leistung:
+99.39%
1-Tages-Spanne:
$50.87
$52.92
1-Wochen-Bereich:
$44.67
$52.92
52-Wochen-Spanne:
$24.95
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Firmenname
Tarsus Pharmaceuticals Inc
Sektor
Branche
Telefon
(949) 409-9820
Adresse
15440 LAGUNA CANYON ROAD, IRVINE
Vergleichen Sie TARS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
52.72 | 2.11B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-20 | Eingeleitet | Goldman | Neutral |
| 2023-07-18 | Eingeleitet | William Blair | Outperform |
| 2023-05-18 | Eingeleitet | Guggenheim | Buy |
| 2022-08-01 | Eingeleitet | Barclays | Overweight |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-23 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-10 | Eingeleitet | BofA Securities | Buy |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-11-10 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Tarsus Pharmaceuticals Inc Aktie (TARS) Neueste Nachrichten
Grading 2 Pharma Stocks That Are Heating Up as Large-Cap Rivals Falter - TheStreet Pro
Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87 - Investor's Business Daily
Tarsus Pharmaceuticals Q2 2025: Key Contradictions on XDEMVY's Market Potential, Discount Strategies, and Seasonal Sales Trends - AInvest
Tarsus Pharmaceuticals’ Earnings Call Highlights XDEMVY Success - TipRanks
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $75 - 富途牛牛
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2025 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates - MSN
Tarsus Pharmaceuticals shares fall 7.01% after-hours following Q2 2025 earnings call. - AInvest
Tarsus Pharmaceuticals Reports Record Q2 Net Sales of $102.66M, Exceeding Consensus - AInvest
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $84 - 富途牛牛
Tarsus Pharmaceuticals: Strong Sales Growth and Strategic Initiatives Drive Buy Rating - TipRanks
Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum - MSN
Tarsus Pharmaceuticals: Scaling a High-Growth Eye Care Platform with a Diversified Pipeline and Strong Commercial Execution - AInvest
Tarsus Pharmaceuticals Sees 95,000-100,000 Bottles Target for Q3 2025 Amid Record-Breaking Sales - AInvest
Tarsus Pharmaceuticals Reports Record Sales Growth - TipRanks
Transcript : Tarsus Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Tarsus 2025 Q2 Earnings Loss Narrows as Revenue Surges 151.5% - AInvest
Tarsus Pharmaceuticals : Second Quarter 2025 Earnings Presentation - MarketScreener
Tarsus Pharmaceuticals Q2 revenue beats expectations - MarketScreener
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - The Globe and Mail
Tarsus Pharmaceuticals Reports Record $102.7 Million in Quarterly Net Product Sales of XDEMVY, a 152% Increase Year Over Year - Quiver Quantitative
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements - Yahoo Finance
Published on: 2025-08-04 16:33:09 - beatles.ru
How does Tarsus Pharmaceuticals Inc. compare to its industry peersProven strategies for superior portfolio growth - Jammu Links News
What are the technical indicators suggesting about Tarsus Pharmaceuticals Inc.Maximize gains with timely market signals - Jammu Links News
Is Tarsus Pharmaceuticals Inc. stock overvalued or undervaluedRapid growth opportunities - Jammu Links News
Why is Tarsus Pharmaceuticals Inc. stock attracting strong analyst attentionBuild wealth steadily with smart stock selection - Jammu Links News
Is Tarsus Pharmaceuticals Inc. a good long term investmentUnlock powerful stock screening for profits - Jammu Links News
Is it the right time to buy Tarsus Pharmaceuticals Inc. stockGet ahead with breakthrough trading ideas - Jammu Links News
When is Tarsus Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid financial growth with smart picks - Jammu Links News
What is the dividend policy of Tarsus Pharmaceuticals Inc. stockUnlock your portfolio’s full growth potential - Jammu Links News
What are the latest earnings results for Tarsus Pharmaceuticals Inc.Phenomenal returns - Jammu Links News
What analysts say about Tarsus Pharmaceuticals Inc. stockBuild a portfolio that withstands market volatility - Jammu Links News
What institutional investors are buying Tarsus Pharmaceuticals Inc. stockInvest confidently with market-leading analysis - Jammu Links News
How strong is Tarsus Pharmaceuticals Inc. company’s balance sheetAchieve breakthrough financial results - Jammu Links News
What makes Tarsus Pharmaceuticals Inc. stock price move sharplyFree Stock Review Backed By Experts - jammulinksnews.com
Is Tarsus Pharmaceuticals Inc. a growth stock or a value stockChart Pattern Data Feed For Beginners - jammulinksnews.com
Tarsus Pharmaceuticals, Inc. to Host Live Webcast for Q2 2025 Financial Results and Corporate Update - Quiver Quantitative
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - GlobeNewswire Inc.
Why Investors Shouldn't Be Surprised By Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) P/S - simplywall.st
Tarsus Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayWeekly Return Pick Forecast Reports Show Trend - metal.it
Tarsus Pharmaceuticals Inc. Charts Flash Early Recovery SignalsNews Based Entry Opportunity Alerts Detected - metal.it
Tarsus Pharmaceuticals Inc. Facing Inflection Point in Trend AnalysisLong Hold Safe Return Strategy Reviewed - metal.it
Wyckoff Accumulation Phase Possible in Tarsus Pharmaceuticals Inc.Chart-Based Trade Entries Gain Analyst Support - metal.it
Evaluating Tarsus Pharmaceuticals Inc. with trendline analysisTechnical Screener for High Growth Stocks - Newser
How Resilient Is Tarsus Pharmaceuticals Inc. Stock During Economic DownturnsBuy Strategy Tracker with Growth Indicators - Newser
Tarsus Pharmaceuticals Inc. Attempts Reversal From Key SupportChart Driven High Reward Trading Setup Presented - metal.it
Why Tarsus Pharmaceuticals Inc. stock attracts strong analyst attentionTrade Safety Matrix for Conservative Traders - Newser
Published on: 2025-07-28 23:18:28 - metal.it
Fibonacci Levels Suggest Recovery for Tarsus Pharmaceuticals Inc.Weekly Chart Analysis With Entry Advice Provided - metal.it
How volatile is Tarsus Pharmaceuticals Inc. stock compared to the marketTriple-digit profit margins - jammulinksnews.com
Finanzdaten der Tarsus Pharmaceuticals Inc-Aktie (TARS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tarsus Pharmaceuticals Inc-Aktie (TARS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Farrow Jeffrey S | See Remarks |
Jun 17 '25 |
Sale |
40.42 |
13,608 |
550,035 |
36,704 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):